Which has higher valuation and earnings, GKOS or RMD?

ResMed has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Glaukos $507.44M 19.45 -$187.69M -$3.25 N/A ResMed $5.65B 5.57 $1.52B $10.43 20.93

Is GKOS or RMD more profitable?

ResMed has a net margin of 26.94% compared to Glaukos' net margin of -30.68%. ResMed's return on equity of 25.58% beat Glaukos' return on equity. Company Net Margins Return on Equity Return on Assets Glaukos -30.68% -6.37% -4.78% ResMed 26.94% 25.58% 18.89%

Does the media refer more to GKOS or RMD?

In the previous week, ResMed had 12 more articles in the media than Glaukos. MarketBeat recorded 15 mentions for ResMed and 3 mentions for Glaukos. ResMed's average media sentiment score of 1.11 beat Glaukos' score of 0.83 indicating that ResMed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Glaukos 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ResMed 13 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, GKOS or DXCM?

DexCom has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Glaukos $507.44M 19.45 -$187.69M -$3.25 N/A DexCom $4.66B 6.72 $836.30M $2.53 32.82

Is GKOS or DXCM more profitable?

DexCom has a net margin of 20.12% compared to Glaukos' net margin of -30.68%. DexCom's return on equity of 35.94% beat Glaukos' return on equity. Company Net Margins Return on Equity Return on Assets Glaukos -30.68% -6.37% -4.78% DexCom 20.12% 35.94% 14.75%

Does the media refer more to GKOS or DXCM?

In the previous week, DexCom had 12 more articles in the media than Glaukos. MarketBeat recorded 15 mentions for DexCom and 3 mentions for Glaukos. DexCom's average media sentiment score of 0.89 beat Glaukos' score of 0.83 indicating that DexCom is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Glaukos 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DexCom 8 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor GKOS or GEHC?

In the previous week, GE HealthCare Technologies had 16 more articles in the media than Glaukos. MarketBeat recorded 19 mentions for GE HealthCare Technologies and 3 mentions for Glaukos. GE HealthCare Technologies' average media sentiment score of 1.40 beat Glaukos' score of 0.83 indicating that GE HealthCare Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Glaukos 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GE HealthCare Technologies 15 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer GKOS or PHG?

Glaukos presently has a consensus target price of $178.08, indicating a potential upside of 6.41%. Given Glaukos' stronger consensus rating and higher possible upside, research analysts clearly believe Glaukos is more favorable than Koninklijke Philips. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Glaukos 1 Sell rating(s) 1 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.79 Koninklijke Philips 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings & valuation, GKOS or PHG?

Koninklijke Philips has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Koninklijke Philips, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Glaukos $507.44M 19.45 -$187.69M -$3.25 N/A Koninklijke Philips $20.17B 1.20 $1.01B $1.36 18.10

Which has higher valuation & earnings, GKOS or STE?

STERIS has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Glaukos $507.44M 19.45 -$187.69M -$3.25 N/A STERIS $5.94B 3.47 $782.30M $8.18 25.81

Is GKOS or STE more profitable?

STERIS has a net margin of 13.34% compared to Glaukos' net margin of -30.68%. STERIS's return on equity of 14.34% beat Glaukos' return on equity. Company Net Margins Return on Equity Return on Assets Glaukos -30.68% -6.37% -4.78% STERIS 13.34% 14.34% 9.66%

Does the media favor GKOS or STE?

In the previous week, Glaukos and Glaukos both had 3 articles in the media. STERIS's average media sentiment score of 1.06 beat Glaukos' score of 0.83 indicating that STERIS is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Glaukos 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive STERIS 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Glaukos (GKOS) Competitors

$167.36 -3.03 (-1.78%)

Closing price 09/11/2026 03:58 PM Eastern

Extended Trading

$167.26 -0.09 (-0.05%)

As of 09/11/2026 07:30 PM Eastern

Compare

GKOS vs. RMD, DXCM, GEHC, PHG, and STE

Should you buy Glaukos stock or one of its competitors? Glaukos's main competitors and comparable companies include ResMed (RMD), DexCom (DXCM), GE HealthCare Technologies (GEHC), Koninklijke Philips (PHG), and STERIS (STE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Glaukos compare to ResMed?

Glaukos (NYSE:GKOS) and ResMed (NYSE:RMD) are both large-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.

99.0% of Glaukos shares are held by institutional investors. Comparatively, 55.0% of ResMed shares are held by institutional investors. 5.9% of Glaukos shares are held by insiders. Comparatively, 0.7% of ResMed shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Glaukos currently has a consensus target price of $178.08, indicating a potential upside of 6.41%. ResMed has a consensus target price of $240.31, indicating a potential upside of 10.09%. Given ResMed's higher possible upside, analysts plainly believe ResMed is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
ResMed	0 Sell rating(s)	10 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.38

ResMed has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$507.44M	19.45	-$187.69M	-$3.25	N/A
ResMed	$5.65B	5.57	$1.52B	$10.43	20.93

In the previous week, ResMed had 12 more articles in the media than Glaukos. MarketBeat recorded 15 mentions for ResMed and 3 mentions for Glaukos. ResMed's average media sentiment score of 1.11 beat Glaukos' score of 0.83 indicating that ResMed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glaukos	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ResMed	13 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ResMed has a net margin of 26.94% compared to Glaukos' net margin of -30.68%. ResMed's return on equity of 25.58% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glaukos	-30.68%	-6.37%	-4.78%
ResMed	26.94%	25.58%	18.89%

Glaukos has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market. Comparatively, ResMed has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market.

Summary

ResMed beats Glaukos on 11 of the 16 factors compared between the two stocks.

How does Glaukos compare to DexCom?

Glaukos (NYSE:GKOS) and DexCom (NASDAQ:DXCM) are both large-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Glaukos has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market. Comparatively, DexCom has a beta of 1.42, meaning that its share price is 42% more volatile than the broader market.

DexCom has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$507.44M	19.45	-$187.69M	-$3.25	N/A
DexCom	$4.66B	6.72	$836.30M	$2.53	32.82

99.0% of Glaukos shares are held by institutional investors. Comparatively, 97.8% of DexCom shares are held by institutional investors. 5.9% of Glaukos shares are held by company insiders. Comparatively, 0.3% of DexCom shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, DexCom had 12 more articles in the media than Glaukos. MarketBeat recorded 15 mentions for DexCom and 3 mentions for Glaukos. DexCom's average media sentiment score of 0.89 beat Glaukos' score of 0.83 indicating that DexCom is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glaukos	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DexCom	8 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

DexCom has a net margin of 20.12% compared to Glaukos' net margin of -30.68%. DexCom's return on equity of 35.94% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glaukos	-30.68%	-6.37%	-4.78%
DexCom	20.12%	35.94%	14.75%

Glaukos presently has a consensus price target of $178.08, suggesting a potential upside of 6.41%. DexCom has a consensus price target of $88.71, suggesting a potential upside of 6.84%. Given DexCom's stronger consensus rating and higher possible upside, analysts plainly believe DexCom is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
DexCom	1 Sell rating(s)	2 Hold rating(s)	21 Buy rating(s)	2 Strong Buy rating(s)	2.92

Summary

DexCom beats Glaukos on 14 of the 17 factors compared between the two stocks.

How does Glaukos compare to GE HealthCare Technologies?

Glaukos (NYSE:GKOS) and GE HealthCare Technologies (NASDAQ:GEHC) are both large-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

GE HealthCare Technologies has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than GE HealthCare Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$507.44M	19.45	-$187.69M	-$3.25	N/A
GE HealthCare Technologies	$20.63B	1.40	$2.08B	$4.36	14.66

In the previous week, GE HealthCare Technologies had 16 more articles in the media than Glaukos. MarketBeat recorded 19 mentions for GE HealthCare Technologies and 3 mentions for Glaukos. GE HealthCare Technologies' average media sentiment score of 1.40 beat Glaukos' score of 0.83 indicating that GE HealthCare Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glaukos	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GE HealthCare Technologies	15 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Glaukos has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market. Comparatively, GE HealthCare Technologies has a beta of 0.7, suggesting that its share price is 30% less volatile than the broader market.

GE HealthCare Technologies has a net margin of 9.33% compared to Glaukos' net margin of -30.68%. GE HealthCare Technologies' return on equity of 20.12% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glaukos	-30.68%	-6.37%	-4.78%
GE HealthCare Technologies	9.33%	20.12%	5.74%

99.0% of Glaukos shares are owned by institutional investors. Comparatively, 82.1% of GE HealthCare Technologies shares are owned by institutional investors. 5.9% of Glaukos shares are owned by insiders. Comparatively, 0.4% of GE HealthCare Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Glaukos presently has a consensus price target of $178.08, suggesting a potential upside of 6.41%. GE HealthCare Technologies has a consensus price target of $77.73, suggesting a potential upside of 21.58%. Given GE HealthCare Technologies' higher possible upside, analysts clearly believe GE HealthCare Technologies is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
GE HealthCare Technologies	0 Sell rating(s)	11 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.48

Summary

GE HealthCare Technologies beats Glaukos on 10 of the 16 factors compared between the two stocks.

How does Glaukos compare to Koninklijke Philips?

Glaukos (NYSE:GKOS) and Koninklijke Philips (NYSE:PHG) are both large-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

Glaukos has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market. Comparatively, Koninklijke Philips has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market.

Glaukos presently has a consensus target price of $178.08, indicating a potential upside of 6.41%. Given Glaukos' stronger consensus rating and higher possible upside, research analysts clearly believe Glaukos is more favorable than Koninklijke Philips.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
Koninklijke Philips	0 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Koninklijke Philips has a net margin of 6.30% compared to Glaukos' net margin of -30.68%. Koninklijke Philips' return on equity of 14.38% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glaukos	-30.68%	-6.37%	-4.78%
Koninklijke Philips	6.30%	14.38%	5.96%

99.0% of Glaukos shares are held by institutional investors. Comparatively, 13.7% of Koninklijke Philips shares are held by institutional investors. 5.9% of Glaukos shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Koninklijke Philips has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Koninklijke Philips, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$507.44M	19.45	-$187.69M	-$3.25	N/A
Koninklijke Philips	$20.17B	1.20	$1.01B	$1.36	18.10

In the previous week, Glaukos had 3 more articles in the media than Koninklijke Philips. MarketBeat recorded 3 mentions for Glaukos and 0 mentions for Koninklijke Philips. Koninklijke Philips' average media sentiment score of 1.00 beat Glaukos' score of 0.83 indicating that Koninklijke Philips is being referred to more favorably in the news media.

Company	Overall Sentiment
Glaukos	Positive
Koninklijke Philips	Positive

Summary

Koninklijke Philips beats Glaukos on 8 of the 15 factors compared between the two stocks.

How does Glaukos compare to STERIS?

Glaukos (NYSE:GKOS) and STERIS (NYSE:STE) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, media sentiment, valuation and earnings.

In the previous week, Glaukos and Glaukos both had 3 articles in the media. STERIS's average media sentiment score of 1.06 beat Glaukos' score of 0.83 indicating that STERIS is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glaukos	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
STERIS	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Glaukos presently has a consensus target price of $178.08, suggesting a potential upside of 6.41%. STERIS has a consensus target price of $271.33, suggesting a potential upside of 28.53%. Given STERIS's higher possible upside, analysts clearly believe STERIS is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
STERIS	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Glaukos has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market. Comparatively, STERIS has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market.

STERIS has a net margin of 13.34% compared to Glaukos' net margin of -30.68%. STERIS's return on equity of 14.34% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glaukos	-30.68%	-6.37%	-4.78%
STERIS	13.34%	14.34%	9.66%

STERIS has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$507.44M	19.45	-$187.69M	-$3.25	N/A
STERIS	$5.94B	3.47	$782.30M	$8.18	25.81

99.0% of Glaukos shares are held by institutional investors. Comparatively, 94.7% of STERIS shares are held by institutional investors. 5.9% of Glaukos shares are held by company insiders. Comparatively, 1.1% of STERIS shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

STERIS beats Glaukos on 10 of the 15 factors compared between the two stocks.

Get Glaukos News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GKOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GKOS vs. The Competition

Export

Metric	Glaukos	Healthcare Equipment & Supplies Industry	Healthcare Sector	NYSE Exchange
Market Cap	$10.05B	$5.44B	$7.15B	$23.19B
Dividend Yield	N/A	1.79%	2.56%	3.56%
P/E Ratio	-51.49	24.63	272.98	28.69
Price / Sales	19.45	70.87	641.55	17.08
Price / Cash	N/A	32.53	77.04	33.82
Price / Book	14.65	5.96	10.33	4.74
Net Income	-$187.69M	$150.14M	$3.49B	$1.07B
7 Day Performance	-6.09%	-2.88%	-3.33%	-1.99%
1 Month Performance	-10.04%	-3.12%	-0.40%	-2.68%
1 Year Performance	102.27%	9.29%	19.15%	10.45%

Glaukos Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GKOS Glaukos	1.8017 of 5 stars	$167.36 -1.8%	$178.08 +6.4%	+91.2%	$10.05B	$507.44M	N/A	1,094	Gap Up
RMD ResMed	4.1411 of 5 stars	$240.03 -0.1%	$240.31 +0.1%	-20.6%	$34.67B	$5.65B	23.01	11,370	Positive News Analyst Forecast Insider Trade
DXCM DexCom	3.4414 of 5 stars	$91.06 +0.3%	$88.71 -2.6%	+9.3%	$34.27B	$4.66B	35.99	11,000	Positive News
GEHC GE HealthCare Technologies	4.4566 of 5 stars	$71.23 -0.7%	$77.73 +9.1%	-18.0%	$32.40B	$20.63B	16.34	54,000	Positive News
PHG Koninklijke Philips	2.9855 of 5 stars	$26.63 -0.3%	N/A	-14.0%	$26.26B	$20.17B	19.62	65,340	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:GKOS) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Glaukos (GKOS) Competitors